

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD303 (BDCA-2)-PE-Vio770, human

RRID:AB_2657198

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-110-321, RRID:AB_2657198

Antibody Information

URL: http://antibodyregistry.org/AB_2657198

Proper Citation: Miltenyi Biotec Cat# 130-110-321, RRID:AB_2657198

Target Antigen: CD303 (BDCA-2)

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution dendritic cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-655. (RRID:AB_2726208).

Antibody Name: CD303 (BDCA-2)-PE-Vio770, human

Description: This monoclonal targets CD303 (BDCA-2)

Target Organism: non-human primate, human

Clone ID: REA693

Antibody ID: AB_2657198

Vendor: Miltenyi Biotec

Catalog Number: 130-110-321

Record Creation Time: 20250820T004805+0000

Record Last Update: 20250820T091406+0000

Ratings and Alerts

No rating or validation information has been found for CD303 (BDCA-2)-PE-Vio770, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution dendritic cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-655. (RRID:AB_2726208).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T??cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 54(6), 1257.